Navigation Links
Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
Date:3/7/2012

BURLINGAME, Calif. and LONGNAN CITY, China, March 6, 2012  /PRNewswire/ -- Apexigen, Inc., a privately held biopharmaceutical company, and Gansu Duyiwei Biological Pharmaceutical Co., Ltd. (GDBP), which is listed on the Shenzhen stock exchange, today announced that they entered into a collaboration to grant an exclusive license to GDBP to develop and commercialize APX004 in China.   APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases.  Under this agreement, GDBP will have an exclusive license and sole responsibility to research, develop and commercialize APX004 in China.  Apexigen retains all rights to APX004 outside of China and will collaborate with GDBP to advance the development program.  Under the terms of the agreement, Apexigen will receive an upfront payment, milestone payments on the successful achievement of regulatory milestones, and a royalty.  Financial terms were not disclosed.

"The pharmaceutical market in China today is very dynamic.  We are pleased to be partnering with Gansu Duyiwei for the development and commercialization of APX004 in this vibrant market.  We're looking forward to a productive partnership," said Dr. Xiaodong Yang, Apexigen's President and CEO.  

"During the last century, people often said that the century to come will be the biological science century.  The report of a survey from an American marketing research institute, Alt Assets, shows that the prospects for the global biotechnology industry are very promising. The sales revenue for products of the bio-economy, that is, products based on biological science and biotechnology, will exceed 15 trillion US Dollars in 30 years and the bio-economy will outrun the information economy and become the most powerful economic force in the world. The cooperation between Duyiwei and Apexigen will become a developmental milestone for Duyiwei. Based on its efforts, flexible mode of R&D and the continually increased investment on R&D, Duyiwei has the confidence and determination to constantly launch a series of original products in the near future to bring hope to the diseased and improve their quality of living," said Dr. Zhiping Duan, CEO of Gansu Duyiwei.

About Apexigen, Inc.

Apexigen, Inc. is an emerging biopharmaceutical company focused on the development of best-in-class antibody therapeutics for the treatment of cancer and other serious diseases.  Apexigen has a robust antibody platform technology and a pipeline of seven humanized antibody product candidates.  Apexigen's proprietary antibody technologies produce a broad diversity of antibodies with high specificity and high affinity against unique epitopes.  It can successfully generate antibodies against challenging antigens where competing technologies fail.  This technology allows Apexigen to identify antibodies with unique functional characteristics for optimal therapeutic benefit.

Developing its product pipeline through collaborations is an important aspect of Apexigen's business model.  Several antibodies derived from its technology have been licensed to companies in China who are developing them for commercialization there.  In addition, Apexigen has also licensed the use of its antibody technologies to multinational companies for use in the development of therapeutics worldwide.  Additional information is available at www.apexigen.com.

About Gansu Duyiwei Biological Pharmaceutical Co., Ltd.

Gansu Duyiwei Biological Pharmaceutical Co., Ltd. is located in Kang County, Longnan city , Gansu Province. As the first pharmaceutical company listed on Shenzhen Stock Exchange in Gansu Province, the company has developed very fast in recent years.

As an important Chinese patent medicine and crude drug company based in west China, its development has been a strong impetus to the rapid development of the local economy. We made outstanding contributions to poverty in the western region. We have been awarded over the years with the titles of "high-tech enterprises in Gansu Province","a key leading enterprise of agricultural industrialization in Gansu Province, and "Longnan excellent enterprise". Our main product is "Duyiwei Capsule" and it has been named as a brand-name product in Gansu Province and a top-quality product in Longnan for three years.

Our products include 11 dosage forms and 32 varieties, most of which are Traditional Chinese Medicine, which provide therapy in the areas of Hemostasis & Analgesia, Cardiovascular system, Respiratory system , Nervous system , Urinary system and so on.

CONTACT:  Mark Nevins, +1-650-931-6236, ext. 502, mnevins@apexigen.com


'/>"/>
SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
2. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
3. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
6. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
7. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
8. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
9. Pharma and Biotech Leaders to Converge in Shanghai
10. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
11. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions ... in the Aragon Research Globe™ for Corporate Learning, 2017. , Aragon Research defines ... market demand, and effectively perform against those strategies. NetDimensions’ ranking as a Leader ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider ... isolation of prostate circulating tumor cells using Vortex microfluidic technology ” in Nature Precision ... collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in establishing ... From her professional foundation as a licensed occupational therapist, through a variety of ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Cambridge Semantics ... splash at this year’s Bio-IT World Conference and Expo in Boston May ... Lake® 4.0 solution. The Anzo Smart Data Lake is also a finalist for ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):